The Analyst Verdict: Stryker In The Eyes Of 11 Experts
Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Stryker (NYSE:SYK) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 3 | 3 | 0 | 0 |
| Last 30D | 2 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 1 | 0 | 0 |
| 3M Ago | 2 | 1 | 2 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $426.27, a high estimate of $465.00, and a low estimate of $392.00. This current average represents a 0.22% decrease from the previous average price target of $427.20.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of Stryker among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Raises | Buy | $454.00 | $448.00 |
| Ryan Zimmerman | BTIG | Raises | Buy | $412.00 | $410.00 |
| Lee Hambright | Bernstein | Raises | Outperform | $465.00 | $450.00 |
| David Turkaly | Citizens | Announces | Market Outperform | $440.00 | - |
| Richard Newitter | Truist Securities | Lowers | Hold | $392.00 | $400.00 |
| Joanne Wuensch | Citigroup | Lowers | Buy | $420.00 | $455.00 |
| Richard Newitter | Truist Securities | Raises | Hold | $400.00 | $392.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $456.00 | $452.00 |
| Mike Matson | Needham | Maintains | Buy | $448.00 | $448.00 |
| Ryan Zimmerman | BTIG | Maintains | Buy | $410.00 | $410.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $392.00 | $407.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stryker. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Stryker compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Stryker's stock. This examination reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Stryker's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Stryker analyst ratings.
Get to Know Stryker Better
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
Understanding the Numbers: Stryker's Finances
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3M period, Stryker showcased positive performance, achieving a revenue growth rate of 10.25% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Stryker's net margin excels beyond industry benchmarks, reaching 14.18%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Stryker's ROE excels beyond industry benchmarks, reaching 4.0%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Stryker's ROA stands out, surpassing industry averages. With an impressive ROA of 1.84%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.76.
The Basics of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.